

Typed or Printed Name of Person Signing Certificate

4. The method of claim 2, wherein the level of nm23 is modulated by administering an nm23 polypeptide-encoding nucleic acid to the cell.

5. A method for screening for a test compound that modulates the Rad-nm23 interaction, comprising:

(a) providing a Rad polypeptide, an nm23 polypeptide, and a test compound; and
(b) detecting an interaction between the Rad polypeptide and the nm23 polypeptide, wherein a difference in the interaction between the Rad polypeptide and the nm23 polypeptide in the presence of the test compound, compared to in the absence of the test compound, is indicative of a compound that modulates the Rad-nm23 interaction.

6. The method of claim 5, wherein the Rad polypeptide or the nm23 polypeptide are provided as a purified polypeptide preparation.

7. The method of claim 5, wherein the Rad polypeptide and the nm23 polypeptide are provided as purified polypeptide preparations.

8. The method of claim 6 or 7, wherein the Rad polypeptide, nm23 polypeptide, and the test compound are provided in vitro.

9. The method of claim 5, wherein the Rad polypeptide or the nm23 polypeptide provided in (a) are expressed in a cell.

10. The method of claim 5, wherein the Rad polypeptide and the nm23 polypeptide provided in (a) are expressed in a cell.

11. The method of claim 9 or 10, wherein the test compound is contacted with the cell.

12. The method of claim 5, wherein detecting the interaction between the Rad polypeptide and the nm23 polypeptide comprises detecting binding of Rad to nm23.

13. The method of claim 5, wherein detecting the interaction between the Rad polypeptide and the nm23 polypeptide comprises detecting a modification of Rad or nm23.

14. The method of claim 13, wherein the modification is phosphorylation of nm23.
15. The method of claim 5, further comprising (c) administering the compound to an animal and optionally (d) evaluating the in vivo effect of the compound on the animal.
16. The method of claim 15, wherein evaluating the in vivo effect of the compound comprises evaluating cell growth in the animal. --

09/053,967-453400

Applicant : Kahn et al.
Serial No. : 09/053,967
Filed : April 2, 1998
Page : 4

Attorney's Docket No.: 10276-017002 / JDP-031 CN

REMARKS

This amendment is being filed together with a continuation application.

The specification has been amended to insert a reference to the parent application.

Claim 1 has been canceled and new claims 2-16 have been added. The claims are supported throughout the application, e.g., at page 1, line 29 to page 2, line 3; and page 5, line 16 to page 6, line 19.

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all claims be examined.

Respectfully submitted,

Date: Feb. 12, 2002

Leda Tiurnos, Reg. No. P-50,635
for: Louis Myers
Reg. No. 35,965

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20388628.doc

20388628.doc

Applicant : Kahn et al.
Serial No. : 09/053,967
Filed : April 2, 1998
Page : 5

Attorney's Docket No.: 10276-017002 / JDP-031 CN

Version with markings to show changes made

In the specification:

Paragraph beginning at page 1, line 5 has been amended as follows:

This application is a continuation of U.S.N.N. 09/053,967, filed April 2, 1998, which claims priority to U.S. provisional Application No. 60/043,983, filed on April 3, 1997, the contents of which are incorporated herein by reference.

09/053,967 - 45,942,001